In the ClarIDHy study, the IDH1 inhibitor ivosidenib demonstrated a clinical benefit in previously treated, advanced IDH1-mutant cholangiocarcinoma [39] and has gained approval for second-line treatment. This evidence concerns the gene IDH1 and cholangiocarcinoma.